CION Ameerpet
Triple-negative breast cancer (TNBC) has none of the three targets — estrogen, progesterone or HER2 — that most breast cancer drugs aim at, so it is treated differently. It is more aggressive than average and more common in younger Indian women, but it is also unusually responsive to chemotherapy, and modern immunotherapy and PARP options have improved outcomes. At CION, a woman-headed, tumor-board-led team builds an accurate, BRCA-informed plan for TNBC — without rushed decisions or unnecessary tests.
Triple-negative breast cancer (TNBC) is a type of invasive breast cancer whose cells test negative on all three of the markers that doctors usually use to guide breast cancer treatment: the estrogen receptor (ER), the progesterone receptor (PR), and the HER2 protein. When a pathologist examines a breast cancer biopsy, they routinely check for these three. If the cancer has none of them, it is called "triple-negative".
This matters because two of the most effective groups of breast cancer drugs — hormone (endocrine) therapy and HER2-targeted therapy — only work when those targets are present. In TNBC they are not, so treatment relies mainly on chemotherapy, and increasingly on immunotherapy and other targeted options. TNBC accounts for about 10–15% of breast cancers worldwide, but Indian studies report a notably higher share — commonly 21–27% — and it tends to appear in younger women.
TNBC describes the biology of the cancer (its receptor status), not how advanced it is. A TNBC can be early-stage or advanced — the subtype and the stage are two separate things.
Globally TNBC is about 10–15% of breast cancers; Indian real-world series report roughly 21–27%, partly because Indian women are diagnosed younger.
The triple-negative result comes from the same biopsy report used to plan all breast cancer treatment — ER, PR and HER2 testing, plus grade and Ki67.
While triple-negative breast cancer is about 10–15% of breast cancers in Western populations, Indian real-world series consistently report a much higher share — commonly 21–27% — and at a younger age. That is one reason BRCA testing and an accurate, team-based plan matter so much for Indian women diagnosed with TNBC. Source: Indian hospital-based breast cancer cohort data; NCCN Breast Cancer guidance.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
The name comes directly from the three tests done on every breast cancer biopsy. Each one tells the oncologist whether a particular treatment will help. "Triple-negative" simply means all three came back negative — so the usual hormone-blocking and HER2-targeting drugs will not work, and the plan has to be built differently.
Understanding what each "negative" means helps you understand why your treatment looks different from a friend's or relative's breast cancer treatment, even though you both have "breast cancer".
Most breast cancers are fuelled by the hormone estrogen and can be slowed with anti-hormone tablets like tamoxifen or aromatase inhibitors. ER-negative tumours do not respond to these, so hormone therapy is not part of TNBC treatment.
The progesterone receptor is the second hormone target checked. In TNBC it is also absent, confirming that hormone (endocrine) therapy will not help this cancer.
HER2 is a protein that, when overactive, drives fast growth and can be blocked by drugs such as trastuzumab. TNBC has normal HER2 levels, so HER2-targeted drugs are not used in standard TNBC treatment.
With no hormone or HER2 target, chemotherapy becomes the backbone of treatment — supported by immunotherapy, and by PARP inhibitors when a BRCA mutation is present. The good news is that TNBC is often very responsive to chemotherapy.
TNBC can affect any woman, but it is clearly more common in some groups. It tends to appear at a younger age than other breast cancers and is strongly linked to inherited BRCA1 gene changes. Knowing whether you fall into a higher-risk group helps your doctor decide who needs genetic testing and earlier, closer attention.
TNBC is more common in women under 40–50 and in premenopausal women. In India, where breast cancer is already diagnosed about a decade younger than in the West, this means many TNBC patients are in their 30s and 40s.
Inherited BRCA1 mutations are strongly associated with TNBC — most BRCA1-related breast cancers are triple-negative. This is the central reason every TNBC patient should be offered genetic testing.
Breast or ovarian cancer in close relatives, especially at a young age, raises the chance that an inherited gene change is involved — and TNBC is the subtype most often seen in these families.
Unlike some cancers, TNBC is not "brought on" by any single habit. Most women who develop it have done nothing wrong — which is exactly why awareness and prompt evaluation matter for everyone.
TNBC does not have unique symptoms of its own — the warning signs are the same as for any breast cancer. But because TNBC can grow quickly, getting any persistent change checked promptly matters even more. Most breast changes are not cancer, yet the ones that are need to be found early.
Often firm and painless, sometimes felt as a thickening. A lump that grows or does not come and go with your period needs review — TNBC lumps can appear and enlarge between mammograms.
Swelling of part of the breast, or a new difference between the two breasts that was not there before.
Puckering, redness, or skin that looks like the peel of an orange (peau d'orange) over the breast.
A newly pulled-in (inverted) nipple, or nipple discharge other than breast milk — especially if it is bloody.
Pain in one spot that is not tied to your menstrual cycle and does not settle over a few weeks.
An aggressive, fast-moving subtype is exactly the situation where a single doctor's opinion is not enough. CION is a woman-headed, tumor-board-led organisation built for these decisions — accurate subtyping, BRCA-informed planning, and a treatment sequence chosen by a full panel rather than one person.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
Woman-led, tumor-board-reviewed, BRCA-informed TNBC care across 35+ centres in Telangana & AP. Call 1800-202-8726.
Yes — on average, TNBC tends to grow faster, is more likely to have spread to lymph nodes at diagnosis, and has a higher chance of returning in the first few years than hormone-positive breast cancers. Most TNBC recurrences happen within the first 3 years, and the great majority within 5 years. We tell patients this honestly, because clear information helps you make good decisions.
But "aggressive" is only half the story, and the other half is genuinely encouraging: TNBC is one of the most chemotherapy-responsive breast cancers. Many TNBCs shrink dramatically — sometimes disappearing entirely — with pre-surgery chemotherapy. That responsiveness, combined with immunotherapy and BRCA-directed drugs, is why outcomes for early TNBC have improved substantially. After about 5 years without recurrence, the risk of it coming back is low.
Because there is no hormone or HER2 target, TNBC treatment is built around chemotherapy — but the order and the additions matter. For most early-stage TNBC, treatment is given as neoadjuvant therapy (before surgery), so the team can see how well the cancer responds and tailor what comes after. Immunotherapy is now added for many patients, and PARP inhibitors are used when a BRCA mutation is present. Surgery and, often, radiation complete the plan.
At CION, this sequence is set by the tumor board for your specific stage and BRCA status — so you get the right drugs in the right order, without unnecessary tests or delay.
Prognosis in TNBC depends heavily on two things: the stage at diagnosis, and how well the cancer responds to chemotherapy given before surgery. The single most powerful predictor is pathologic complete response (pCR) — when, after neoadjuvant chemotherapy, the surgeon and pathologist find no remaining invasive cancer in the breast or lymph nodes. Patients who achieve pCR have markedly better long-term outcomes, which is a major reason TNBC is treated with chemo first.
Stage-by-stage, 5-year survival for TNBC is reported at roughly 91–92% for localized disease, around 65–67% for regional (node-positive) disease, and lower once it has spread to distant organs. These are population averages — your own outlook depends on your stage, your response to treatment, and your BRCA status. At CION, 1-year survival outcomes for breast cancer run meaningfully ahead of the national average.
CION breast cancer 1-year survival: 96.9% vs national average 85.4% (+11.5%). *1-year survival. Source: ICMR / National Cancer Registry Programme (NCRP).
Genetic testing is not an optional extra for TNBC — it is a core part of good care. International guidelines recommend offering BRCA testing to anyone diagnosed with triple-negative breast cancer, regardless of age or family history, because TNBC is the subtype most strongly linked to inherited BRCA1 mutations. The result can change your treatment, your surgery, and your family's future.
At CION, BRCA testing is discussed up front for TNBC patients, with genetic counselling so you understand what the result means before and after the test.
A triple-negative diagnosis moves fast, and the decisions made in the first few weeks matter. You do not have to navigate them alone. CION offers a clear, woman-led pathway from first consultation to treatment, built around your stage and your BRCA status — with your first consultation free.
A specialist reviews your biopsy and reports in full, explains what "triple-negative" means for you, and outlines the likely plan — no rushed decisions, no unnecessary tests.
We confirm the ER/PR/HER2 status, grade and Ki67, and arrange BRCA testing with genetic counselling — up to 50% discounts on diagnostics.
3+ oncologists plan your treatment together — typically neoadjuvant chemo (with immunotherapy where appropriate), surgery, radiation, and PARP inhibitors if you are BRCA-positive.
Chemotherapy, surgery, radiation, immunotherapy and targeted therapy as needed — with nutrition, psycho-oncology and transparent costs throughout your care.
Hear from patients treated at CION — diagnosis, treatment path, and where they are today.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.Triple-negative breast cancer (TNBC) is a breast cancer whose cells test negative for all three of the markers doctors normally target: the estrogen receptor, the progesterone receptor, and the HER2 protein. Because those three targets are missing, the usual hormone-blocking tablets and HER2 drugs do not work, so treatment is built mainly around chemotherapy, often with immunotherapy and — for BRCA carriers — PARP-inhibitor tablets. TNBC makes up about 10–15% of breast cancers worldwide, but a higher share (around 21–27%) in Indian women, and it tends to appear at a younger age.
On average, yes. TNBC tends to grow faster, is more likely to have reached the lymph nodes at diagnosis, and has a higher chance of returning in the first 3 years than hormone-positive breast cancers. We share this honestly. But the other half of the story is encouraging: TNBC is one of the most chemotherapy-responsive breast cancers, so it often shrinks dramatically with treatment given before surgery. Modern immunotherapy and BRCA-directed drugs have further improved outcomes. After about 5 years without recurrence, the ongoing risk becomes low.
Early-stage TNBC can often be treated with the goal of cure, and many women are cured. Because TNBC responds strongly to chemotherapy, a large proportion of patients achieve a "pathologic complete response" — no invasive cancer remaining after pre-surgery chemo — which is linked to excellent long-term survival. Localized TNBC has a 5-year survival around 91–92%. Advanced (metastatic) TNBC is generally not curable but is treatable, with chemotherapy, immunotherapy, PARP inhibitors and antibody-drug conjugates used to control it and extend life. Your outlook depends on stage, treatment response and BRCA status — which is why an accurate, team-based plan matters.
Most breast cancers can be treated with hormone therapy or HER2-targeted drugs, but TNBC has none of those targets — so those drug groups simply do not work. What TNBC does have is strong sensitivity to chemotherapy. For most early TNBC, chemotherapy is given before surgery (neoadjuvant), which shrinks the tumour, can allow breast-conserving surgery, and reveals how well the cancer responds. For many patients an immunotherapy drug is added to the chemo, and BRCA carriers may also receive PARP-inhibitor tablets. So chemotherapy is not a "last resort" in TNBC — it is the most effective backbone available.
Yes — guidelines recommend offering BRCA testing to everyone diagnosed with triple-negative breast cancer, regardless of age or family history, because TNBC is the subtype most strongly linked to inherited BRCA1 mutations. The result matters in three ways: it can make you eligible for PARP-inhibitor treatment, it can influence your surgery decision (a positive result raises the risk of a future second breast cancer), and it lets your relatives consider their own testing and prevention. Testing should always come with genetic counselling. At CION, BRCA testing and counselling are built into the TNBC pathway from the start.
pCR stands for "pathologic complete response". It means that after chemotherapy given before surgery (neoadjuvant treatment), the surgeon and pathologist find no remaining invasive cancer in the breast or lymph nodes. In triple-negative breast cancer, achieving pCR is the single strongest predictor of long-term survival — patients who reach it do significantly better than those who do not. This is the main reason TNBC is usually treated with chemotherapy first: it lets the team measure the response and tailor what comes after. Adding immunotherapy to chemo increases the chance of achieving pCR for many patients.
TNBC tends to occur at a younger age than other breast cancers. It is more common in premenopausal women and women under 40–50, and it is especially associated with inherited BRCA1 mutations, which themselves cause cancer earlier. In India, where breast cancer is already diagnosed roughly a decade younger than in the West, many TNBC patients are in their 30s and 40s. That said, TNBC can occur at any age. Because younger women are not covered by routine screening, knowing your normal and getting any persistent breast change checked promptly is the most important protective step.
Yes. CION offers a free first consultation for all cancer patients, including women newly diagnosed with TNBC or seeking a second opinion. It is a full 45-minute consultation — a specialist reviews your biopsy and reports, explains what "triple-negative" means for your treatment, arranges BRCA testing with counselling, and gives you a clear, tumor-board-backed plan. There are no rushed decisions and no unnecessary tests, and CION offers up to 50% discounts on diagnostics. You can book on 1800-202-8726 or request a callback through the form on this page.